Reason for request
Inclusion on the list of medicines reimbursed by National Insurance (B/5 and B/20) and approved for use by hospitals (B/5, B/20 and B/30).
Clinical Benefit
| Low |
the actual benefit of VERSATIS 5% lidocaine plasters in the treatment of PHN is low in view of its weak efficacy demonstrated versus placebo. |
Clinical Added Value
| no clinical added value |
VERSATIS offers no improvement in actual benefit compared to the current treatment strategy (IAB V). |
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
y2pL5BDwepQ9stpy
Listen
